CD274 and neoplasm: Several studies have shown that PD‐L1 expression assessed by immunohistochemistry (IHC), tumor mutational burden (TMB) by NGS, microsatellite instability (MSI) by PCR or NGS, as well as deficient mismatch repair (dMMR) by IHC were associated with response to cancer immune checkpoint blockade treatment.7, 8, 9